Daniela Brina
Bellinzona, TI, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Prostate cancer: evading immunity, inspiring therapy.
Journal: Trends in cancer
Published: March 23, 2026
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer.
Journal: Cancer cell
Published: December 06, 2023
Targeting senescence induced by age or chemotherapy with a polyphenol-rich natural extract improves longevity and healthspan in mice.
Journal: Nature aging
Published: June 11, 2023
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.
Journal: Nature cancer
Published: May 09, 2022
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer.
Journal: Cancer cell
Published: April 12, 2022
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Journal: Cancer research
Published: October 04, 2021
Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma.
Journal: Nature communications
Published: July 08, 2020
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Journal: Cancer cell
Published: February 25, 2020
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.
Journal: Nature genetics
Published: August 10, 2018
High levels of eukaryotic Initiation Factor 6 (eIF6) are required for immune system homeostasis and for steering the glycolytic flux of TCR-stimulated CD4+ T cells in both mice and humans.
Journal: Developmental and comparative immunology
Published: May 14, 2017
Last Updated: 09/26/2026